The Administrative Core (Core A) will support the scientific and programmatic activities of our IPCAVD Program and provide the necessary infrastructure for the Program to achieve its overall research objectives and milestones In the most efficient and effective manner. Core A has the following specific aims: (1) to provide scientific leadership and coordination of the IPCAVD's activities, assuring achievement of our scientific goals while maximizing scientific collaboration;(2) to optimize communication among the participating Scientific and Clinical investigators;between Project Leaders, the External Advisory Committee, the NIAID and our Clinical Partners;and (3) to provide fiscal oversight, administrative support, and ensure regulatory and grant policy compliance. Core A will be led by the Principal Investigator, Dr. Leonidas Stamatatos, who will manage, oversee and coordinate the efforts of each participant in the Program, with the assistance of the Project Manager. A group of external Scientific Advisors will be formed to oversee the scientific activities of the IPCAVD and provide advice and support. This Core will oversee and integrate the execution of the Research Plans, Product Development Plan, and Clinical Development Plan. Core A oversees all aspects of this Program including scientific issues, regulatory affairs, finance, communication, coordination and administration of each of the Cores and Projects. This Core will ensure that expenditures and projections are commensurate with the goals of the overall project;monitor the fiscal and functional aspects of all subcontracts;and coordinate with the Offices of Sponsored Research at participating Institutions for the disbursement, expenditure and accounting of grant funds. This Core will coordinate the preparation and submission of scientific and financial reports, facilitate the establishment of regulatory protocols and ensure regulatory compliance. Communications will be facilitated utilizing a variety of tools, including a dedicated, external IPCAVD SharePoint site, which will serve as a centralized repository for Program data, regulatory compliance documents, inter-institutional and material transfer agreements and relevant publications, abstracts and presentations.
The Administrative Core will provide the necessary infrastructure for the IPCAVD Program to achieve its overall research objectives and milestones, leading to the development of an HIV vaccine which elicits broadly neutralizing antibody responses.
|Escolano, Amelia; Dosenovic, Pia; Nussenzweig, Michel C (2017) Progress toward active or passive HIV-1 vaccination. J Exp Med 214:3-16|
|Horwitz, Joshua A; Bar-On, Yotam; Lu, Ching-Lan et al. (2017) Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell 170:637-648.e10|
|Escolano, Amelia; Steichen, Jon M; Dosenovic, Pia et al. (2016) Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell 166:1445-1458.e12|
|Yacoob, Christina; Pancera, Marie; Vigdorovich, Vladimir et al. (2016) Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. Cell Rep 17:1560-1570|
|McGuire, Andrew T; Gray, Matthew D; Dosenovic, Pia et al. (2016) Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun 7:10618|
|Tian, Ming; Cheng, Cheng; Chen, Xuejun et al. (2016) Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166:1471-1484.e18|
|Dosenovic, Pia; von Boehmer, Lotta; Escolano, Amelia et al. (2015) Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell 161:1505-15|
|McGuire, Andrew T; Dreyer, Anita M; Carbonetti, Sara et al. (2014) HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346:1380-1383|